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Abstract
Background: Brucellosis affects human populations in many developing countries including the
Middle East, and Latin America where it is still endemic. It has been prevalent in Jordan for years,
where 7842 cases of human brucellosis were registered at the Ministry of Health during 10 year-
period. This study was initiated by the recent increase in the number of human cases diagnosed in
a rural area in the Northern Jordan to help assess the status of the disease in that area. For this
purpose blood specimens from brucellosis suspected cases were tested by serology, culture and
PCR.
Methods: Peripheral blood specimens from 50 healthy control subjects and 165 seropositive
patients having compatible signs and symptoms that were clinically diagnosed to have brucellosis
were tested by blood culture, and by PCR. The PCR assay used genus-specific primers from the
conserved region of the 16S rRNA sequence, which showed high specificity for the Brucella spp.
Results: Diagnosis of Brucella was established by PCR in 120 cases (72.7%). All of them were
seropositive and 20 were positive by culture. Forty-eight of 58 (82.8%) of the relapsed cases two
months after completing the treatment with an increase in the previous serological titers were
positive by PCR. The assay has 85.7% positive predicative value, 100% sensitivity and specificity
since it correctly identified all cases that were positive by blood cultures, 95.8% by serology and
none of the control group was positive.
Conclusions: Results showed that PCR assay can be applied with serology for the diagnosis of
brucellosis suspected cases and relapses regardless of the duration or type of the disease without
relying on the blood cultures, especially in chronic cases.
Background
Brucellosis continues to be an important zoonosis of eco-
nomic significance and human suffering. It affects human
populations in many developing countries including the
Middle East, and Latin America where it is still endemic
[1]. The World Health Organization reports an annual in-
cidence of human brucellosis of less than one to 78 cases
per 100,000 population in the Middle East, with six coun-
tries reporting an annual total incidence of more than
90,000 cases [2]. Four Brucella spp. namely, Brucella abor-
tus, B. canis, B. suis and especially B. melitensis are able to
cause human infections [3]. Brucellosis is usually trans-
mitted to humans by ingestion of unpasteurized dairy
products or by direct contact with infected animals. Occu-
pational disease is contracted by exposure of abattoir
workers and veterinarians to infected animals especially
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countries, the incidence of human brucellosis has de-
clined in the last 50 years as a result of infection control
measures, and in these countries most cases result from
occupational disease, travel-acquired infections, or acci-
dental laboratory exposure through contaminated aero-
sols [3]. According to the World Health Organization, half
a million new human cases each year are reported world-
wide [4]. These numbers greatly underestimate the true in-
cidence of human disease [3] because the clinical picture
of human brucellosis is extremely variable [5], and be-
cause it is under declared to local authorities and misdiag-
nosed by clinicians.
Brucella spp. are able to cause prolonged morbidity due to
the capability of this bacteria to evade the host defense
mechanisms by surviving as intracellular organisms. The
diagnosis of the disease can be challenging and is fre-
quently delayed or missed because the clinical picture
may mimic other infectious and noninfectious conditions
[6,7]. Diagnosis can be established by laboratory methods
such as serology and blood cultures. Prolonged incuba-
tion period, special growth media, and subcultures are re-
quired for the isolation of these fastidious, slow growing
bacteria. However, cultures are not always positive when
other tests are positive [8]. Automated systems have been
reported to detect more than 95% of Brucella melitensis-
positive cultures within seven days of incubation [7]. The
technology is lacking in developing countries or rural are-
as where the disease is prevalent and diagnoses rely main-
ly on serology. Many serological tests have been used for
the diagnosis of human brucellosis such as agglutination
tests, indirect immunofluorescence, ELISA. The most
commonly used tests are the serum agglutination test
(SAT), the Coombs anti-Brucella test, the Rose Bengal test,
and complement fixation [9]. Each test has its own disad-
vantages, and the presence of antibodies doesn't always
mean an active case of brucellosis, since humans from en-
demic areas often show weak serological responses [8]. As
for other fastidious pathogens, amplification of DNA by
PCR offers an alternative way of diagnosis of brucellosis.
Brucellosis has been prevalent in Jordan fo r years, where
7842 cases of human brucellosis were registered at the
Ministry of Health during 10 year-period, from January
1988 to 1997 [10]. Ovine and caprine brucellosis caused
by Brucella melitensis have been present in sheep and goat
flocks in the bedouin sector for years. The number of cases
has increased considerably in the mid to late 1980s. The
increase might partially be attributed to improved diag-
nostic methods.
This study was initiated by the recent increase in the
number of human cases diagnosed in the health centers in
a rural area in the Northern Jordan Badia to help assess the
status of the disease in that area. For this purpose blood
specimens from brucellosis suspected cases were cultured
and tested with PCR assay using a genus-specific primer
pair derived from the conserved region of the16S rRNA se-
quence which showed high specificity for the Brucella spp.
[8]. The results are compared with that of the blood cul-
tures and the Rose Bengal agglutination test.
Methods
Clinical specimens
A total of 215 peripheral blood specimens was collected
from patients in four comprehensive health centers over a
period of 18 months. Of these blood specimens, 165 were
from patients who presented with clinical signs compati-
ble with brucellosis. Clinical diagnosis was made by the
physicians in the Badia of Jordan, a rural area in the north
east of Jordan inhabited by recently settled Bedouins.
These centers receive patients from 40 villages with a pop-
ulation exceeding 12,000 inhabitants. The diagnosis of
brucellosis is established based on the presence of com-
patible signs and symptoms with the demonstration of
specific antibodies at significant titer or seroconversion.
The physicians are aware of the zoonotic nature of the dis-
ease because of the continuous reporting of the disease in
sheep, goats and in humans in this area. Sixty (36.4%) of
the samples were collected after adequate antibiotic treat-
ment was started.
A questionnaire was completed for each subject at the
time of specimen collection to record demographic and
other relevant information such as the clinical history,
symptoms and physical signs, contact with animals,
drinking unpasteurized milk, and homemade dairy
products.
The duration of symptoms prior to diagnosis was 1 to 16
weeks. Cases with clinical symptoms less than two
months were considered as acute cases, those that lasted
more than 6 months before treatment was initiated were
considered as chronic cases. A relapse was considered to
be either a positive blood culture two months to one year
after completing the treatment or the reappearance of
compatible symptoms not otherwise explained together
with an increase in the previous serological titers. All pa-
tients had fever during the course of the disease with other
symptoms such as muscle pain, wrist arthritis.
Treatment of recent cases is by a combination of a daily in-
tramuscular injection of one gram of streptomycin for 14
days and doxycycline for a month. In the chronic cases, a
combination of doxycycline and rifampin is given to the
patient for one month according to the internationally ac-
cepted treatment regimens [11]. The treatment was repeat-
ed when the symptoms persist and antibody titer was still
high two weeks after concluding the treatment.Page 2 of 7
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Samples were obtained from 50 subjects, composed of pa-
tients randomly selected among patients from the same
region attending the same health centers. None of these
patients was currently diagnosed or had a history of
brucellosis.
The study was approval by the University ethics
committee.
Serological techniques
The serological tests were carried out by the laboratories of
the health centers. The serologic diagnosis was established
by Rose Bengal agglutination test. A titer of 1/160 was
considered positive.
Blood cultures
Five to ten ml peripheral blood samples were withdrawn
and immediately inoculated under aseptic conditions in
broth media (Bloodgrow®, Medical Wire & Equipment C.
Ltd, Corsham, Wiltshire, England) or diphasic blood cul-
ture bottles (Hemoline performance diphasique bioMer-
ieux, Marcy l'Etoile, France). Cultures were incubated at
37°C for 30 days in the presence of 5% CO2 and were pe-
riodically checked for growth. Subcultures on blood agar
plates were performed in a blind manner at 10, 20, 30
days, they were recorded as negative after the last negative
subculture. Brucella spp. were identified using standard
methods [12].
DNA extraction
DNA was extracted from blood specimens using a com-
mercial purification system (Wizard Genomic DNA Puri-
fication Kit, Promega, Madison, WI) according to the
manufacturer's instructions for DNA purification from
blood. Final pellets were resuspended in 50 l of TE (10
mM Tris, I mM EDTA, pH 7.2).
PCR assay
The Brucella DNA-Detect PCR Kit (Vita-Tech International
Inc., CAN), including the reagents and oligonucleotid
primers designed for the direct amplification of the genus
Brucella, was used for the detection of Brucella spp. in
blood samples. The primers used in the kit were genus-
specific primer pair designed to amplify a highly con-
served region within the 16S rRNA of the genus Brucella
[8].
The size of the amplification products was a 905 fragment
of the rRNA gene. The reaction mixture contained 5 µl of
10 × PCR buffer, 1 µl of the primer mix, 2 µl of dNTP mix
(5 mM each), 3 µl of 25 mM MgCl2, 1 unit of Taq DNA
polymerase, 5 µl of sample DNA in a volume of 50 µl. The
same mixtures were used with the positive control provid-
ed by the kit. The mixture with no DNA sample, and DNA
free water were used as negative controls to monitor
contamination.
The reaction was performed in a thermal cycler (Gene
Amp PCR System 9700, Perkin Elmer, Norwalk, Con.).
The cycling conditions were an initial denaturation at
95°C for 5 min, template denaturation at 95°C for 30s,
annealing at 54°C for 90s, and primer extension at 72°C
for 90s for a total of 35 cycles, with a final extension at
72°C for 6 min. A sample was considered positive when
the size of the DNA band matched with that of the po si-
tive control (905 bp). All standard precautions recom-
mended for prevention of contamination with DNA and
amplicons were undertaken. Twelve microliters of the
PCR product were run by electrophoresis in a 2% agarose
gel in 1 × TBE buffer (Promega, Madison, Wis.), and gels
were stained with ethidium bromide (2 µg/ml).
PCR amplification products were detected by visualiza-
tion of the bands under UV light.
Statistical analysis
The means, ranges, percentages of positive samples, spe-




The mean age of the patients was 46 years (range, 6 to 86
years). Of these patients, 58 (35.2%) were males and 107
(64.8%) were females. The information recorded in the
questionnaire indicated that, out of 165 patients included
in this study, 66 (40%) had contact with animals (e.g.,
sheep and goats) either raised nearby where they live or at
work (e.g., farmers). Seventy-four (44.9%) acquired their
infections by consuming unpasteurized milk or home-
made dairy products (e.g., soft cheese), 32 (19.4%) ac-
quired their infection possibly from contact with animals
as mentioned above, 24 (14.5%) acquired their infection
possibly from one of these two sources.
The other 35 (21.2%) patients acquired their infection
from unknown sources, since they either drink pasteur-
ized milk, do not drink milk, or drink powder milk, and
had no homemade cheese. Two of the patients drink cam-
el milk.
The mean duration of symptoms before diagnosis of the
brucellosis was 35 days (range 10–60 days) in 140
(84.8%) of the cases (Table 1). The duration for the other
25 (15.2%) was more than 60 days. Fifty-eight (35.2%) o
f the previously treated pat ients had symptoms suggestive
of a relapse within a year after concluding treatment.
These patients had symptoms consistent with brucellosis
with an increase in antibody titers and no otherPage 3 of 7
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to the information provided in the questionnaire.
Serology
One hundred and forty (84.9%) of these patients were
positive by Rose Bengal agglutination test with titers rang-
ing between 1/1 60 and 1/1280 units. The 25 clinical cases
who were seronegative were not included in the group of
certainly infected patients.
The number of patients who were tested for Brucella anti-
bodies in that area during the study was 1050, they had
symptoms consistent with brucellosis, but only 452
(43%) were positive at the time they were tested.
Blood cultures
Brucella was isolated in blood cultures from 20 of the 165
(12%) blood specimens who didn't receive antibiotic
treatment at the time the specimen was colleted. Isolates
were identified by standard methods as B. melitensis. These
samples were positive by both PCR and serology.
PCR assay
One hundred and twenty (72.7%) of the 165 samples
were positive by PCR. These patients had symptoms for
more than one month t o several years and were all posi-
tive by serology; recent infections of less than one month
were negative by PCR. The DNA bands that appeared in
the acute cases were brighter than those of the chronic
cases.
The PCR was negative on conclusion of the treatment for
25 of the 45 negative patients. The other twenty negative
patients were suspected cases who were recently diag-
nosed based on signs and symptoms. They were still neg-
ative by serology and by culture and hence, these patients
could not be considered as true infections (Table 2).
Forty-eight (82.8%) of the 58 relapsed cases were positive
by PCR and by serology. The positive predicative value
(e.g., t he proportion of true positive among all positives)
of the assay was 85.7% based on the serology results.
Control samples
None of the 50 subjects was positive by serology or by
PCR.
The sensitivity of the PCR assay is 85.7% compared to se-
rology and the specificity is 100% since all the control
subjects were negative.
Table 1: Epidemiological, clinical, and serological results of 165 cases of human brucellosis.
Characteristics Values
No. of patients studied 165
Male: Female 1:1.85
Mean age in years (range) 45.5 (5–86)
Clinical and laboratory diagnosis:
Mean duration of the chronic cases in years (range) 8.5 (1–16)
No. of patients with fever 165/165 (100%)
No. of patients with muscle pain and anorexia 140/165 (84.8%)
No. of relapsed patients 58/165 (35.2%)
No. of positives in Rose Bengal agglutination test (1/160) 140/165 (84.8%)
No. of patients with positive blood cultures 20/165 (12%)
No. of patients with positive PCR 120/165 (72.7%)
No. of relapsed patients with positive PCR 48/58 (82.8%)
Table 2: Comparison of the PCR results with blood culture and serology for the165 cases
Result of tests Seroa, Cult b Sero, Cult Sero, Cult Sero, Cult Total
+ + + - - + - -
PCR + 20 100 0 0 120
PCR - 0 20 0 25 45
Total 20 120 0 25 165
a Serology: Rose Bengal agglutination test (titer, $1/160) b Cult: blood culturePage 4 of 7
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Although brucellosis is a notifiable disease in many coun-
tries, official figures do not fully reflect the number of cas-
es reported annually, and the true incidence has been
estimated to be between 10 and 25 times higher than
what the reported figures indicate [13].
The increase in the incidence of human cases was linked
to the lambing season in Jordan [10,14]; these reports are
in agreement with the findings of the current study.
Bedouins are at higher risks of contracting brucellosis, due
to the lifestyle, environmental and social conditions of
this population [15].
Diagnosis of human brucellosis based on the clinical pic-
ture alone is not definitive since the symptoms mimic oth-
er diseases and is fairly nonspecific. The isolation of the
organism in culture or detection by molecular methods is
necessary to confirm the clinical diagnosis. There are few
studies concerning the use of PCR technique in animals
[16,17], the studies of human cases are limited and the
number of patients included was small [3,18,19]. The
present work studied the potential use of a single-step
PCR assay as a rapid test for the diagnosis of acute, chronic
infections, and a relapse in previously treated patients. Pa-
tients were also studied by means of blood cultures, Rose
Bengal agglutination. In many laboratories the serological
diagnosis of human as well as animal brucellosis is based
on a Rose Bengal test, which was improved from being a
screening test to be a titrable one [20].
One of the genetic targets frequently used for strain iden-
tification and strain phylogeny is the rRNA operon, partic-
ularly the 16S rRNA gene used in this study. These genes
are highly conserved and diverge very slowly. The DNA se-
quences from separate species within a genus will differ by
only a few percent. Sequence identity among 16S rRNA se-
quences is typically interpreted as indicating a single spe-
cies [21]. A PCR assay with primers derived from the 16S
rRNA sequence of Brucella abortus was developed [8]. The
specificity and high sensitivity of this assay provide a val-
uable tool for the diagnosis of brucellosis.
The PCR results confirmed the clinical diagnosis in 120
(72.7%) patients, the results obtained by serology in 120/
140 (85.7%) and by blood cultures in 20/20 (100%). It
correctly diagnosed 48/58 (82.8%) of the relapse cases
who were identified based on the symptoms and the in-
crease in the antibody titer after completing the treatment.
It can reduce the time needed for blood cultures and its
limitations caused by the low number or bacteria in the
blood especially in chronic and focal type of the disease
[22]. The assay was able to detect Brucella DNA in cases of
acute, chronic and relapsed brucellosis. The DNA bands in
chronic cases were weak most probably due to low num-
bers of Brucella in the peripheral blood. The same results
were reported by a previous study in serum samples ob-
tained from staff of cattle breeding centers [23].
Twenty of the forty-five cases that were negative by PCR
were recently diagnosed cases of brucellosis (< one
month). These cases were negative both by serology and
by blood cultures, indicating that they are true negatives.
The other 25 samples were negative by the three methods,
which might be due to the absence of infection, the possi-
bility of temporary or episodic lack of bacteremia in bru-
cellosis patients, the stage or nature of the disease, or the
treatment that lowers the number of bacterial cells in the
peripheral blood beyond detection. The therapy can mod-
ify PCR, culture, and serology results and therefore these
cases should constitute a category different from those
where samples were taken before therapy.
Several factors were reported to inhibit PCR in a blood
specimen such as the high concentrations of leukocytes
DNA and heme compounds [19].
The sensitivity of the PCR assay was 100% based on the re-
sults of the 20 patients who were positive by both serology
and blood culture and 85.7% based on the number of pa-
tients who were positive by serology alone. The specificity
of the assay was 100% since none of the 50 control blood
samples was positive by PCR. The threshold sensitivity for
the PCR assay was reported to be from 80 ng to 0.08 fg [8]
as determined by testing serial dilutions of B. abortus 2308
DNA detected aft er 40 cycles of amplification. Similar
findings with respect to the amount of Brucella DNA de-
tected by PCR have been obtained by using primer se-
quences from the genes encoding a 43-kDa outer
membrane protein [24] and a 31-kDa B. abortus antigen
[18]. It was suggested that 60 to 100 fg of bacterial DNA is
equivalent to 20 cells [25]. The importance of this finding
is based on the fact that low numbers of circulating Bru-
cellae are present in focal and chronic forms of the disease
that are difficult to detect by culture and leads to a subop-
timal recovery rate of Brucella from blood.
The PCR test proved t o be useful in the early detection of
relapses as was reported by another [18]. study [26]. The
diagnosis of these relapses is difficult by conventional
methods Relapses after concluding a correct treatment are
known to occur in brucellosis [3,27]. This problem is
related to the ability of Brucella spp. to evade some of the
basic mechanisms of the host's immune system [26]. The
relapse rate of 32.5% of the pat ients after a combined
treatment could be explained in part by lack of
compliance in some patients to the full course of treat-
ment. This is common in such rural communities where
Bedouins show up for treatment several weeks after hav-
ing symptoms and discontinue treatment once the feverPage 5 of 7
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la organisms localize in the reticuloendothelial system af-
ter surviving the intracellular mechanisms by phagocytes
and polymorphonuclear leukocytes [3,28]. A combina-
tion regimen of two or three drugs is more effective than
a single-drug regimen. The relapse rate may be as high as
50% in cases of single-drug regimens [28,29]. Longer
courses of therapy are required to cure relapses and focal
forms of the disease such as meningitis and ost eomyelitis.
The po sitive PCR results obtained in the 48 (82.8%) of
the relapse cases in this study is especially important indi-
cating that the assay co uld be a useful tool to confirm a
relapse in cases of a treated brucellosis. However, due to
the extremely high sensitivity of the technique, the ability
to amplify the DNA of non-viable, non-culturable Brucella
DNA from dead or phagocytized cells especially the re-
mains of DNA present in the circulating mononuclear
cells in certain patients who have concluded successful-
treatment [26] should be considered when interpreting
the results.
The criteria to indicate a cure of brucellosis is not definite,
since negative blood cultures do not exclude the presence
of the disease. Another study reported recovering the bac-
teria in 53.4% to 95% blood cultures of patients but suc-
cessful isolation of the organism decreased over time [7].
Other specimens from bone marrow and liver tissue or
lymph nodes may improve recovery rates [3], but these
specimens are invasive and are not always feasible. Anti-
bodies may remain elevated for a long time after conclu-
sion of the treatment [30], which was noticed in some o f
the chronic cases in this study that were negative by PCR.
Conclusion
The results of this study are in agreement with several pre-
vious studies [8,18,22,26] that reported on the usefulness
of PCR and recommended its use for the diagnosis of ini-
tial episodes, focal complications, post treatment follow-
up, and relapses.
The peripheral-blood-based PCR assay described is highly
sensitive and specific, easy to perform, and could provide
results to a clinician in less than 8 h. In addition, it avoids
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